KIR3DL1-based inhibitory CAR NK cell therapy alleviates on-target, off-tumor toxicity with retention of antitumor effects
BackgroundChimeric antigen receptor (CAR) T cell therapy has significantly improved outcomes in hematologic malignancies. However, its translation to solid tumors is hampered by on-target, off-tumor toxicity (OTOT) and antigen escape. These obstacles u…